EUVIMEDEUVIMED entdecken
Crossref

L26/O-159 Preimplantation genetic testing for aneuploidy in POSEIDON Group 4: benefit or harm?

X. Liu

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von X. Liu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question To investigate whether preimplantation genetic testing for aneuploidy (PGT-A) benefits women classified in POSEIDON Group 4. Summary answer PGT-A did not improve pregnancy/live birth rates but reduced miscarriage rates vs non-PGT-A. What is known already ART use rises in advanced-age women, with embryos prone to chromosomal abnormalities and poor outcomes. PGT-A benefits some but lacks data in POSEIDON Group 4 (≥35y, low AFC/AMH). These patients have few oocytes/blastocysts; PGT-A may reduce miscarriage but risks cycle failure, creating clinical dilemmas. Study design, size, duration This retrospective PSM cohort study included 54,122 POSEIDON Group 4 women undergoing first IVF (2020–2024). PGT-A and non-PGT-A groups were matched 1:3. Outcomes: biochemical/clinical pregnancy, miscarriage, ectopic pregnancy, live birth rates per transfer/retrieval. Participants/materials, setting, methods PGT-A (trophectoderm biopsy + NGS) and non-PGT-A groups were 1:3 PSM-matched. Outcomes (per transfer/retrieval): biochemical/clinical pregnancy, miscarriage, ectopic pregnancy, live birth rates (analyzed via SPSS, RRs + 95% CIs). Main results and the role of chance PGT-A had comparable biochemical pregnancy per transfer (risk ratio [RR]: 0.75, 95% confidence interval [95% CI], 0.43-1.18) and per retrieval (RR: 0.75, 95% CI, 0.41-1.19). While PGT-A group also had similar clinical pregnancy per transfer (RR: 0.75, 95% CI, 0.36-1.20) and per retrieval (RR: 0.75, 95% CI, 0.38-1.23), they achieved significantly lower miscarriage per transfer (RR: 0.17, 95% CI, 0.00-0.59) and per retrieval (RR: 0.17, 95% CI, 0.00-0.58). However, live birth rates were similar both in per transfer (RR: 0.89, 95% CI, 0.35-1.65) and per retrieval (RR: 0.89, 95% CI, 0.39-1.69). Limitations, reasons for caution Retrospective design limits causal inference. Potential unmeasured confounders exist. Generalizability may be restricted to POSEIDON Group 4 women at tertiary centers. Wider implications of the findings For POSEIDON Group 4 patients, PGT-A reduces miscarriage risk without improving live birth rates, offering evidence-based guidance for personalized ART decision-making in this high-risk subgroup. Trial registration number No

Zitieren

APA

Liu, X. (2026). L26/O-159 Preimplantation genetic testing for aneuploidy in POSEIDON Group 4: benefit or harm?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.157

Vancouver

Liu X. L26/O-159 Preimplantation genetic testing for aneuploidy in POSEIDON Group 4: benefit or harm?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.157

BibTeX
@article{Liu2026,
  author = {Liu, X.},
  title = {L26/O-159 Preimplantation genetic testing for aneuploidy in POSEIDON Group 4: benefit or harm?},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.157}
}
Kostenlos starten →